Business
OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium
OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium.
About this update from Oncosec Medical Incorporated
[{"type":"text","content":"\n\n\n\nOncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium\nPR Newswire\nSAN DIEGO, May 20, 2015\n\n\n\nSAN DIEGO, May 20, 2015 /PRNewswire/ -- OncoSec Medical Inc. (\"OncoSec\") (OTCQB: ONCSD), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and preclinical studies at the New York Academy of Sciences' Emerging Approaches to Cancer Immunotherapy. OncoSec's Chief Scientific Officer Robert H. Pierce, MD, and Chief Medical Officer Mai. H. Le, MD, will present an abstract entitled: \"Intratumoral Expression of Plasmid IL-12 Can Increase CD8 TILs and Drive Systemic Anti-Tumor Responses: Rationale for Combination with Anti-PD-1 Blockade\" as part of a poster presentation beginning at 12:10 PM ET on Thursday, May 21, 2015 in New York City. \n\nThe poster presentation will discuss the unmet medical need of \"anti-PD-1 non-responders,\" which are characterized by the absence of immune cells, and the role of interventions that are specifically focused on increasing tumor-infiltrating lymphocytes (TILs). By increasing TILs and promoting tumor immunogenicity, these interventions may convert anti-PD-1 non-responders to responders. Intratumoral electroporation-mediated gene therapy with DNA-based IL-12 has demonstrated single-agent anti-tumor efficacy in both preclinical tumor models as well as Phase I and II clinical trials in advanced melanoma. The data highlighted in this presentation suggest that intratumoral delivery of DNA-based IL-12 followed by electroporation can increase CD8 TILs, promote tumor immunogenicity, drive systemic anti-tumor responses, and increase the patient population who may benefit from therapeutic PD-1/PD-L1 blockade.\n\nAbstract information is as follows: \n\n\nTitle: Intratumoral Expression of Plasmid IL-12 Can Increase CD8 TILs and Drive Systemic Anti-Tumor Responses: Rationale for Combination with...